Background: High expression of SETD1A, a histone methyltransferase that specifically methylates H3K4, acted as a key oncogene in several human cancers. However, the function and underlying molecular mechanism of SETD1A in ovarian cancer (OV) remain markedly unknown. Methods: The expression of SETD1A in OV were detected by Western blot and analyzed online, and the prognosis of STED1A in OV were analyzed online. The protein and mRNA levels were determined by Western blot and RT-qPCR. The cell proliferatin, migration and invasion were measured by CCK-8 and transwell assays. The protein interaction was detected by co-IP assay. The interaction between protein and DNA was performed by ChIP assay. The tumor growth in vivo was performed by xenograft tumor model. Results: SETD1A was overexpressed in OV and a predictor of poor prognosis. Overexpression of SETD1A augmented the abilities of cell proliferation, migration, and invasion in MRG1 and OVCAR5 cells. In comparison, SETD1A knockdown suppressed cell growth, migration, and invasion in SKOV3 and Caov3 cells. Specifically, SETD1A enhanced Notch signaling by promoting the expression of Notch target genes, such as Hes1, Hey1, Hey2, and Heyl. Mechanistically, SETD1A interacted with Notch1 and methylated H3K4me3 at Notch1 targets to enhance Notch signaling. In addition, restoration of Notch1 in SETD1A-knockdown OV cells recovered cell proliferation, migration and invasion, which was inhibited by SETD1A knockdown. Furthermore, reduction of SETD1A suppressed tumorigenesis in vivo. Conclusion: In conclusion, our results highlighted the key role of SETD1A in OV development and proved that SETD1A promotes OV development by enhancing Notch1 signaling, indicating that SETD1A may be a novel target for OV treatment.
7 June 2021 in Frontiers in Cell and Developmental Biology
Aberrant epigenetic modification induces oncogene expression and promotes cancer development. The histone lysine methyltransferase SETD1A, which specifically methylates histone 3 lysine 4 (H3K4), is involved in tumor growth and metastasis, and its ectopic expression has been detected in aggressive malignancies. Our previous study reported that SETD1A promotes gastric cancer (GC) proliferation and tumorigenesis. However, the function and molecular mechanisms of SETD1A in GC metastasis remain to be elucidated. In this study, we found that overexpression of SETD1A promoted GC migration and invasion, whereas knockdown of SETD1A suppressed GC migration and invasion in vitro. Moreover, knockdown of SETD1A suppressed GC epithelial-mesenchymal transition (EMT) by increasing the expression of epithelial marker E-cadherin and decreasing the expression of mesenchymal markers, including N-cadherin, Fibronectin, Vimentin, and α-smooth muscle actin (α-SMA). Mechanistically, knockdown of SETD1A reduced the EMT key transcriptional factor snail expression. SETD1A was recruited to the promoter of snail, where SETD1A could methylate H3K4. However, knockdown of SETD1A decreased the methylation of H3K4 on the snail promoter. Furthermore, SETD1A could be a coactivator of snail to induce EMT gene expression. Rescue of snail restored SETD1A knockdown-induced GC migration and invasion inhibition. In addition, knockdown of SETD1A suppressed GC metastasis in vivo. In summary, our data revealed that SETD1A mediated the EMT process and induced metastasis through epigenetic reprogramming of snail.
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent chronic liver condition globally, driving the need to identify prognostic risk factors. The creatinine clearance rate (CCR) serves as a sensitive early marker of glomerular filtration rate. Yet evidence regarding its specific association with mortality in MASLD patients remains limited. Method: The predictive value of the CCR for long-term survival was evaluated in a five-year cohort of adults with MASLD from Pudong District, Shanghai. Baseline characteristics were analyzed, and Kaplan–Meier survival analysis, LASSO regression, restricted cubic splines (RCS), and Cox proportional hazards models were employed to assess the relationship between the CCR and mortality risk, with sensitivity analyses conducted to test robustness. Results: Among 8,828 MASLD patients, a higher CCR was inversely associated with cardiovascular mortality (HR = 0.95; 95% CI: 0.95–0.96) and all-cause mortality (HR = 0.97; 95% CI: 0.96–0.97) (both P < 0.001). Compared to the lowest tertile (T1), the middle (T2) and highest (T3) tertiles showed lower risks ( P for trend < 0.05). RCS analysis revealed a non-linear correlation for both outcomes ( P for non-linearity < 0.05). Kaplan–Meier curves confirmed higher survival probabilities in the highest CCR tertile (log-rank P < 0.001). LASSO regression was used for variable selection and CCR was included in the multivariate prognostic model, suggesting that this index is valuable for model fitting and can serve as an auxiliary indicator for predicting mortality risk in patients with MASLD, which was supported by ROC analysis. Sensitivity analyses confirmed the stability of these findings. Conclusion: In this cohort of Shanghai adults with MASLD, a higher estimated creatinine clearance rate was independently associated with a significantly reduced risk of all-cause and cardiovascular mortality. CCR may serve as a valuable renal function-related prognostic marker for risk stratification in the MASLD population.